Immunomodulation in female B6C3F1mice following treatment with the HIV protease inhibitor saquinavir for 28 days by gavage

Guo, Tai L.; Germolec, Dori R.; Roesh, Denise M.; White, Kimber L.

doi:10.3109/1547691x.2010.495097

Cited by 3 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Host resistance to the B16F10 melanoma tumor was assessed as described previously (Guo et al 2010). Briefly, on day 29 of Elmiron ® treatment, the mice were injected i.v.…”

Section: Methodsmentioning

confidence: 99%

Immunomodulatory activity of orphan drug Elmiron® in female B6C3F1/N mice

Thakur

Nyska

White

et al. 2014

Food and Chemical Toxicology

Self Cite

View full text Add to dashboard Cite

Interstitial cystitis (IC) is a chronic disorder characterized by bladder discomfort and urinary urgency in the absence of identifiable infection. Despite the expanding use in treatment of IC and other chronic conditions, the effects of Elmiron® treatment on immune system remain unknown. Therefore, female B6C3F1/N mice were orally administered Elmiron® daily for 28-days at doses of 63, 125, 250, 500 or 1000 mg/kg to evaluate its immunomodulatory effects. Mice treated with Elmiron® had a significant increase in absolute numbers of splenic macrophages (63, 500 and 1000 mg/kg) and natural killer (NK) cells (250 and 1000 mg/kg). Elmiron® treatment did not affect the humoral immune response or T cell proliferative response. However, innate immune responses such as phagocytosis by liver macrophages (1000 mg/kg) and NK cell activity were enhanced (500 and 1000 mg/kg). Further analysis using a disease resistance model showed that Elmiron® -treated mice demonstrated significantly increased anti-tumor activity against B16F10 melanoma cells at the 500 and 1000 mg/kg doses. Collectively, we conclude that Elmiron® administration stimulates the immune system, increasing numbers of specific cell populations and enhancing macrophage phagocytosis and NK cell activity in female B6C3F1/N mice. This augmentation may have largely contributed to the reduced number of B16F10 melanoma tumors.

show abstract

“…Host resistance to the B16F10 melanoma tumor was assessed as described previously (Guo et al 2010). Briefly, on day 29 of Elmiron ® treatment, the mice were injected i.v.…”

Section: Methodsmentioning

confidence: 99%